This article has been corrected from an earlier version that said that Sequenom had "shelved" its SEQure Dx test following an investigation into mishandled data. The firm is continuing development of the test.

NEW YORK (GenomeWeb News) – Sequenom said after the market closed today that its third-quarter revenues dropped 20 percent while its net loss increased 43 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.